Skip to main content
Log in

Preliminary Evidence for Sociotropy and Autonomy in Relation to Antidepressant Treatment Outcome

  • Original Paper
  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

Sociotropy and autonomy are cognitive-personality styles that have been hypothesized to confer vulnerability to different presentations of major depressive disorder (MDD), which may respond differentially to treatment. Specifically, the profile of low sociotropy and high autonomy is hypothesized to indicate a positive response to antidepressant medication. The current study examines sociotropy and autonomy in relation to sertraline treatment response in individuals with MDD. As part of an ancillary study to the larger Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) project, individuals with MDD participated in an 8-week trial of sertraline and completed a self-report questionnaire of sociotropy and autonomy. Discriminant function analyses were used to examine whether sociotropy and autonomy scores could distinguish antidepressant treatment responders (determined by a 50% or greater reduction in depressive symptoms) from non-responders. The sociotropy scale successfully discriminated sertraline treatment responders from non-responders. Further, lower sociotropy was associated with greater improvements in depressive symptomology following sertraline treatment. The current findings suggest individuals with MDD characterized by low sociotropy are more likely to benefit from sertraline. Given the promising results of the Sociotropy-Autonomy Scale in discriminating treatment responders from non-responders, the low resources necessary for administration, and the ease of translation into routine clinical care, the scale warrants further research attention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bagby RM, Gilchrist EJ, Rector NA, Dickens SE, Joffe RT, Levitt A, Levitan RD, Kennedy SH. The stability and validity of the sociotropy and autonomy personality dimensions as measured by the revised personal style inventory. Cognit Ther Res. 2001;25(6):765–79. https://doi.org/10.1023/A:1012975524455.

    Article  Google Scholar 

  2. Beck AT. Cognitive therapy of depression: new perspectives. In: Clayton PJ, Barnett JE, editors. Treatment of depression: old controversies and new approaches. New York: Raven Press; 1983. p. 265–90.

    Google Scholar 

  3. Clark DA, Beck AT. Personality factors in dysphoria: a psychometric refinement of beck’s sociotropy-autonomy scale. J Psychopathol Behav Assess. 1991;13(4):369–88. https://doi.org/10.1007/BF00960448.

    Article  Google Scholar 

  4. Clarke DE, Kuhl EA. DSM-5 cross-cutting symptom measures: a step towards the future of psychiatric care? World Psychiatry. 2014;13:314–6. https://doi.org/10.1002/wps.20154.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin N Am. 1996;19(2):179–200. https://doi.org/10.1016/S0193-953X(05)70283-5.

    Article  CAS  Google Scholar 

  6. First MB, Spitzer R, Gibbon M, William J. Structured clinical interview for DSM-IV-TR axis I disorders−non-patient edition (SCID-I/NP). New York: Biometric Research Department New York State Psychiatric Institute; 2002.

    Google Scholar 

  7. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–96. https://doi.org/10.1111/j.2044-8260.1967.tb00530.x.

    Article  CAS  PubMed  Google Scholar 

  8. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75:336–46. https://doi.org/10.1001/jamapsychiatry.2017.4602.

    Article  PubMed  PubMed Central  Google Scholar 

  9. IBM Corp. IBM SPSS statistics for windows (No. 26). Armonk: NY IBM Corp; 2019.

    Google Scholar 

  10. Moore RG, Blackburn IM. The stability of sociotropy and autonomy in depressed patients undergoing treatment. Cognit Ther Res. 1994;20:69–80. https://doi.org/10.1007/BF02229244.

    Article  Google Scholar 

  11. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157:1423–8. https://doi.org/10.1176/appi.ajp.157.9.1423.

    Article  CAS  PubMed  Google Scholar 

  12. Peselow ED, Robins CJ, Sanfilipo MP, Block P, Fieve RR. Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy. J Abnorm Psychol. 1992;101:479–86. https://doi.org/10.1037/0021-843X.101.3.479.

    Article  CAS  PubMed  Google Scholar 

  13. Peselow ED, Sanfilipo MP, Difiglia C, Fieve RR. Melancholic/endogenous depression and response to somatic treatment and placebo. Am J Psychiatry. 1992;149:1324–34. https://doi.org/10.1176/ajp.149.10.1324.

    Article  CAS  PubMed  Google Scholar 

  14. Pizzagalli DA, Webb CA, Dillon DG, et al. Pretreatment rostral anterior cingulate cortex theta activity in relation to symptom improvement in depression: a randomized clinical trial. JAMA Psychiatry. 2018;75:547–54. https://doi.org/10.1001/jamapsychiatry.2018.0252.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Robins CJ, Block P, Peselow ED. Relations of sociotropic and autonomous personality characteristics to specific symptoms in depressed patients. J Abnorm Psychol. 1989;98:86–8. https://doi.org/10.1037/0021-843X.98.1.86.

    Article  CAS  PubMed  Google Scholar 

  16. Robins CJ, Luten AG. Sociotropy and autonomy: differential patterns of clinical presentation in unipolar depression. J Abnorm Psychol. 1991;100:74–7. https://doi.org/10.1037/0021-843X.100.1.74.

    Article  CAS  PubMed  Google Scholar 

  17. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–83. https://doi.org/10.1016/s0006-3223(02)01866-8.

    Article  PubMed  Google Scholar 

  18. Rush AJ, Kraemer H, Sackeim H, et al. Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31:1841–53. https://doi.org/10.1038/sj.npp.1301131.

    Article  PubMed  Google Scholar 

  19. Scott J, Harrington J, House R, Ferrier IN. A preliminary study of the relationship among personality, cognitive vulnerability, symptom profile, and outcome in major depressive disorder. J Nerv Ment Dis. 1996;184:503–5. https://doi.org/10.1097/00005053-199608000-00008.

    Article  CAS  PubMed  Google Scholar 

  20. Thase ME, Ninan PT, Musgnung JJ, Trivedi MH. Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. Prim Care Companion J Clin Psychiatry. 2011;13.https://doi.org/10.4088/PCC.10m00979blu

  21. Thomas L, Kessler D, Campbell J, Morrison J, Peters TJ, Williams C, Lewis G, Wiles N. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br J Gen Pract J R Coll Gen Pract. 2013;63:852–8. https://doi.org/10.3399/bjgp13X675430.

    Article  Google Scholar 

  22. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40. https://doi.org/10.1176/appi.ajp.163.1.28.

    Article  PubMed  Google Scholar 

  23. Trivedi MH, McGrath PJ, Fava M, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design. J Psychiatr Res. 2016;78:11–23.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study was supported by NIMH grants U01MH092221 (PI: MHT) and U01MH092250 (PIs: McGrath, Parsey, and Weissman). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was supported by the EMBARC National Coordinating Center at UT Southwestern Medical Center, Madhukar H. Trivedi, M.D., Coordinating PI, and the Data Center at Columbia and Stony Brook Universities, and a Rackham Graduate Student Research Grant.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Margo W. Menkes.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cardinale, R., Menkes, M.W., Andrews, C.M. et al. Preliminary Evidence for Sociotropy and Autonomy in Relation to Antidepressant Treatment Outcome. Psychiatr Q 92, 1069–1077 (2021). https://doi.org/10.1007/s11126-021-09891-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11126-021-09891-1

Keywords

Navigation